The oligonucleotide therapeutic industry is preparing for a pivotal transition as synthetic therapies gain validation and become feasible for large-scale commercial production. The push comes with a call for manufacturers to deepen their expertise in Chemistry, Manufacturing, and Control (CMC) aspects of bioprocessing workflows, according to a report from Genetic Engineering News.
Industry experts underscore that while these therapies have demonstrated clinical promise, scaling up manufacturing requires rigorous CMC oversight to ensure consistency, purity, and potency. The focus on CMC reflects a maturation of the field, moving beyond early-stage development into commercial reality.
Manufacturers are being urged to invest in specialized training and process development to meet regulatory expectations. CMC considerations span raw material sourcing, synthesis protocols, purification, and analytical methods tailored to the unique chemistry of oligonucleotides.
This heightened emphasis on CMC is a natural consequence of the industry's growth, as several oligonucleotide-based drugs have secured regulatory approvals and more are in late-stage pipelines. The shift signals a broader infrastructure buildout, with companies competing to establish reliable, scalable production lines.
However, challenges remain in standardizing CMC approaches across a fragmented ecosystem of drug developers and contract manufacturers. Heterogeneity in manufacturing processes could slow the pace of new drug approvals and limit patient access. Experts caution that without industry-wide collaboration on best practices, scaling may prove uneven.